ACTR 087/rituximab combination therapy - Unum Therapeutics

Drug Profile

ACTR 087/rituximab combination therapy - Unum Therapeutics

Alternative Names: ACTR 087/rituximab combination therapy; ACTR087 + rituximab - Unum Therapeutics; ACTR087 + rituximab combination therapy; CD16V-41BB-CD3ζ; Viral ACTR + rituximab - Unum Therapeutics

Latest Information Update: 01 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unum Therapeutics
  • Class Antineoplastics; Gene therapies; Immunotherapies; Monoclonal antibodies; T lymphocyte cell therapies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors; Immunologic cytotoxicity; Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 01 Jan 2018 Phase-I clinical trials in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (unspecified route) (NCT03266692)
  • 09 Dec 2017 Drug interactions, updated safety and efficacy data from a phase I trial in Non-Hodgkin's lymphoma presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-2017)
  • 01 Nov 2017 Efficacy and adverse events data from a phase I trial in Non-Hodgkin's lymphoma released by Unum Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top